Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Abstract: Pyrimidine derivatives of formula pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

Abstract: A method for determining an ultrasonic detecting cycle is provided. Firstly, an initial detecting cycle T is set. Then, a first sensing wave is generated. Then, a first time-of-flight value is calculated corresponding to the first sensing wave. After the first sensing wave has been generated for the initial detecting cycle T, a second sensing wave is generated. Then, a second time-of-flight value is calculated corresponding to the second sensing wave. Afterwards, the second time-of-flight value is compared with the first time-of-flight value. If a difference between the second time-of-flight value and the first time-of-flight value is smaller than a threshold value, the initial detecting cycle T is determined as the ultrasonic detecting cycle.

Abstract: This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.

Abstract: Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R2, G, G?, and G? represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are also disclosed and claimed.

Abstract: Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R2, G, G?, and G? represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are also disclosed and claimed.

Abstract: A mobile station is provided. The mobile station includes one or more radio transceiver module and a processor. The processor performs a handover negotiation procedure with a serving base station so as to handover communication services to a target base station by transmitting and receiving a plurality of handover negotiation messages via the radio transceiver module, and generates an Authorization Key (AK) context and derives at least one Traffic Encryption Key (TEK) for the target base station. The AK context includes a plurality of keys shared with the target base station for encrypting messages to be transmitted to the target base station, and the TEK is a secret key shared with the target base station for encrypting traffic data.

Abstract: A mobile station is provided. The mobile station includes one or more radio transceiver module and a processor. The processor generates an Authorization Key (AK) context including at least one secret key shared with a base station, transmits at least one association negotiation message via the radio transceiver module to the base station to obtain an association of a service flow established by the base station, and generates at least one TEK according to the secret key and an identifier associated with the association. The service flow is established for traffic data transmission with the base station and the TEK is a secret key shared with the base station for encrypting and decrypting the traffic data.

Abstract: Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R2, G, G?, and G? represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are also disclosed and claimed.

Abstract: Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R2, G, G?, and G? represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are also disclosed and claimed.

Abstract: This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.

Abstract: A lavatory jet assembly for a lavatory having an upper rim and defining a top opening therewithin, comprising a mounting base, jet unit and jet adjusting arrangement, such that the lavatory jet assembly allows a user to choose, after urination or defecation, from the buttons on a control stand to control the jet flowing time and the protruding length of the jet, to control the movement of the driving shaft which is connected to a servo motor or the stepping motor, and simultaneously control the jet which is installed to a side to move to the desired position, so as to automatically washes the excretion organ area of the user.

Abstract: The restaurant ordering system employing RFID of the invention comprises a central database, at least an ordering device, at least a serving device, at least a managing device, at least a RFID customer tag, and at least a RFID dish tag, wherein, the central database is used for storing customer information, personalized menus for frequent customers, payment programs, customer codes and dish codes; the order device further comprises a display and a RFID reader; the serving device further comprises a display and a RFID reader; the managing device further comprises a display and a RFID reader; the RFID customer tag is being used as the customer code; the RFID dish tag is being used as the dish code; and the central database, the ordering device, the serving device and the managing device are connected by an Ethernet.

Abstract: Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R2, G, G?, and G? represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are also disclosed and claimed.